Oncode Scientific

Generic selectors
Exact matches only
Search in title
Search in content
  • SOLID TUMOUR
    ONCODEcipher Series
  • BLOOD CANCERS
    ONCODEduce Series
  • COVID-19
    RT-PCR TEST
  • RISK
    ASSESSMENT

CancerProduct NameTest DescriptionSample RequirementTATCat. No.
Lung CancerLung PlatinumS0001 Lung Liquid28 NGS Panel + S0002 Lung Absolute 2.0 NGS Panel1) 15ml Blood in cfDNA tubes
2) FFPE Block OR 10 Unstained Slides
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS003P
Lung GoldS0002 Lung Absolute 2.0 NGS Panel + S0003 Lung Essential67 NGS Panel1) FFPE Block OR 20 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS004P
Lung Liquid28 NGS Panel Liquid biopsy NGS (ctDNA) panel targeting 28 clinically relevant and actionable genes associated with lung cancer1) 15ml Blood in cfDNA tubes
2) HPE report (optional)
10 Working Days
S0001
Lung Absolute 2.0 NGS Panel NGS (TNA) panel targeting 15 genes commonly mutated in lung cancer for fusions (ALK, ROS1, MET, RET, NTRK etc.) & mutations (EGFR, ERBB2, KRAS, BRAF, ALK etc.)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working Days
S0002
Lung Essential67 NGS PanelNGS (DNA) expanded panel targeting 67 clinically relevant and actionable genes (including mutations of the RAS/ RAF/MEK/MAP kinase signaling pathway)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0003
Colon & Endometrial Cancer Colon & Endometrial Platinum S0006 Colon & Endometrial Essential67 NGS Panel + S0017 Colon & Endometrial MSI PCR Panel1) FFPE Block OR 10-15 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS005P
Colon & Endometrial
Gold
S0016 Colon & Endometrial Core28 NGS Panel
+ S0017 Colon & Endometrial MSI PCR Panel
1) FFPE Block OR 10-15 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS006P
Colon & Endometrial Liquid28 NGS Panel Liquid biopsy NGS (ctDNA) panel targeting 28 clinically relevant and actionable genes associated with colon & endometrial cancers1) 15ml Blood in cfDNA tubes
2) HPE report (optional)
10 Working DaysS0004
Colon & Endometrial Core28 NGS PanelNGS (DNA) panel targeting 28 clinically relevant and actionable genes (BRAF, KRAS, TP53 etc.)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0016
Colon & Endometrial Essential67 NGS PanelNGS (DNA) expanded panel targeting 67 clinically relevant and actionable genes (including mutations of the RAS/ RAF/MEK/MAP kinase signaling pathway)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0006
Colon & Endometrial BRAF PCR Panel PCR method to detect BRAF mutation at V600E hotspot in colon & endometrial cancer1) FFPE Block OR 5 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0005
Colon & Endometrial MSI PCR Panel PCR & Fragment Analysis based assays detecting microsatellite instability status for treatment options in colon & endometrial cancer1) FFPE Block OR 5 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS0017
Breast & Ovarian CancerBreast & Ovarian PlatinumS0018 Breast & Ovarian Core28 NGS Panel
+ S0019 Breast & Ovarian BRCA1/2 Germline NGS & MLPA Panel
+ S0020 Breast & Ovarian MSI PCR Panel
1) FFPE Block OR 10-15 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
12-15 Working DaysS007P
Breast & Ovarian GoldS0007 Breast & Ovarian Liquid28 NGS Panel
+ S0019 Breast & Ovarian BRCA1/2 Germline NGS & MLPA Panel
1) 15ml Blood in cfDNA tubes
2) HPE report (optional)
12-15 Working DaysS008P
Breast & Ovarian Liquid28 NGS Panel Liquid biopsy NGS (ctDNA) panel targeting 28 clinically relevant and actionable genes associated with breast & ovarian cancers1) 15ml Blood in cfDNA tubes
2) HPE report (optional)
10 Working DaysS0007
Breast & Ovarian Core28 NGS Panel NGS (DNA) panel targeting 28 clinically relevant and actionable genes (Somatic BRCA1/2, ESR1, PIK3CA, TP53 & etc.)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0018
Breast & Ovarian Essential67 NGS PanelNGS (DNA) expanded panel targeting 67 clinically relevant and actionable genes (including mutations of the RAS/ RAF/MEK/MAP kinase signaling pathway)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0008
Breast & Ovarian BRCA1/2 Germline NGS & MLPA Pane NGS (DNA) panel targeting inherited BRCA 1 & 2 mutations with 100% coverage for all exons and exon/intron junctions through CNV analysis and MLPA technique to detect regulatory region & deep intronic mutations, large deletions/ duplications & large genomic rearrangement (LGR)1) 3ml Blood in EDTA tube(s)12-15 Working DaysS0019
Breast & Ovarian MSI PCR Panel PCR & Fragment Analysis based assays detecting microsatellite instability status for treatment options in breast & ovarian cancers1) FFPE Block OR 5 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS0020
Prostate CancerProstate ImpactS0026 Prostate Core28 NGS Panel + S0027 Prostate BRCA1/2 Germline NGS & MLPA Panel1) FFPE Block OR 10 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
12-15 Working DaysS011P
Prostate Core28 NGS PanelNGS (DNA) panel targeting 28 clinically relevant and actionable genes1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0026
Prostate BRCA1/2 Germline NGS & MLPA Panel NGS (DNA) panel targeting inherited BRCA 1 & 2 mutations with 100% coverage for all exons and exon/intron junctions through CNV analysis and MLPA technique to detect regulatory region & deep intronic mutations, large deletions/ duplications & large genomic rearrangement (LGR)1) 3ml Blood in EDTA tube(s)12-15 Working DaysS0027
Melanoma ImpactS0028 Melanoma Essential67 NGS Panel
+ S0030 Melanoma MSI PCR Panel
1) FFPE Block OR 10-15 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS012P
Melanoma Essential67 NGS PanelNGS (DNA) expanded panel targeting 67 clinically relevant and actionable genes (including mutations of the RAS/ RAF/MEK/MAP kinase signaling pathway)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0028
Melanoma BRAF PCR Panel PCR method to detect BRAF mutation at V600E hotspot in melanoma1) FFPE Block OR 5 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0029
Melanoma MSI PCR Panel PCR & Fragment Analysis based assays detecting microsatellite instability status for treatment options in melanoma1) FFPE Block OR 5 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS0030
Pancreatic CancerPancreatic PlatinumS0021 Pancreatic Core28 NGS Panel + S0023 Pancreatic BRCA1/2 Germline NGS & MLPA Panel
+ S0024 Pancreatic MSI PCR Panel
1) FFPE Block OR 10-15 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
12-15 Working DaysS009P
Pancreatic GoldS0022 Pancreatic Liquid28 NGS Panel
+ S0023 Pancreatic BRCA1/2 Germline NGS & MLPA Panel
1) 15ml Blood in cfDNA tubes
2) HPE report (optional)
12-15 Working DaysS010P
Pancreatic Liquid28 NGS Panel Liquid biopsy NGS (ctDNA) panel targeting 28 clinically relevant and actionable genes associated with pancreatic cancer1) 15ml Blood in cfDNA tubes
2) HPE report (optional)
10 Working DaysS0022
Pancreatic Core28 NGS PanelNGS (DNA) panel targeting 28 clinically relevant and actionable genes1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0021
Pancreatic Essential67 NGS PanelNGS (DNA) expanded panel targeting 67 clinically relevant and actionable genes (including mutations of the RAS/ RAF/MEK/MAP kinase signaling pathway)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0025
Pancreatic BRCA1/2 Germline NGS & MLPA Panel NGS (DNA) panel targeting inherited BRCA 1 & 2 mutations with 100% coverage for all exons and exon/intron junctions through CNV analysis and MLPA technique to detect regulatory region & deep intronic mutations, large deletions/ duplications & large genomic rearrangement (LGR)1) 3ml Blood in EDTA tube(s)12-15 Working DaysS0023
Pancreatic MSI PCR Panel PCR & Fragment Analysis based assays detecting microsatellite instability status for treatment options in pancreatic cancer1) FFPE Block OR 5 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS0024
Thyroid CancerThyroid ImpactS0032 Thyroid Combo NGS Panel
+ S0031 Thyroid Essential67 NGS Panel
+ S0033 Thyroid MSI PCR Panel
1) FFPE Block OR 20-25 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS013P
Thyroid Combo NGS PanelNGS (TNA) panel targeting 15 genes commonly mutated in thyroid cancer for fusions (ALK, ROS1, MET, RET, NTRK etc.) & mutations (EGFR, ERBB2, KRAS, BRAF, ALK etc.)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0032
Thyroid Essential67 NGS PanelNGS (DNA) expanded panel targeting 67 clinically relevant and actionable genes (including mutations of the RAS/ RAF/MEK/MAP kinase signaling pathway)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0031
Thyroid MSI PCR Panel PCR & Fragment Analysis based assays detecting microsatellite instability status for treatment options in thyroid cancer1) FFPE Block OR 5 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS0033
Other solid tumourLiquid28 + MSIS0009 Liquid28 NGS Panel
+ S0012 MSI PCR Panel
1) 15ml Blood in cfDNA tubes
2) FFPE Block OR 5 Unstained Slides
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS001P
Liquid28 +Combo + MSIS0009 Liquid28 NGS Panel
+ S0014 Combo NGS Panel
+ S0012 MSI PCR Panel
1) 15ml Blood in cfDNA tubes
2) FFPE Block OR 15 Unstained Slides
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS015P
Essential67 + MSIS0011 Essential67 NGS Panel
+ S0012 MSI PCR Panel
1) FFPE Block OR 10-15 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS002P
Combo + Essential67 + MSIS0014 Combo NGS Panel
+ S0011 Essential67 NGS Panel
+ S0012 MSI PCR Panel
1) FFPE Block OR 20-25 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS014P
Combo + Core28S0014 Combo NGS Panel
+ S0015 Core28 NGS Panel
1) FFPE Block OR 20 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS016P
Core28 + BRCAS0015 Core28 NGS Panel
+ S0034 BRCA1/2 Germline NGS & MLPA Panel
1) FFPE Block OR 10 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
12-15 Working DaysS017P
Liquid28 NGS Panel Liquid biopsy NGS (ctDNA) panel targeting 28 clinically relevant and actionable genes commonly mutated in all solid tumours1) 15ml Blood in cfDNA tubes
2) HPE report (optional)
10 Working DaysS0009
Combo NGS PanelNGS (TNA) panel targeting 15 genes commonly mutated in all solid tumours for fusions (ALK, BRAF, EGFR, FGFR, ROS1, MET, RET, NRG1, NTRK etc.) & mutations (EGFR, ERBB2, KRAS, RET, ROS1, BRAF, ALK etc.)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0014
Core28 NGS PanelNGS (DNA) panel targeting 28 clinically relevant and actionable genes commonly mutated in all solid tumours1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0015
Essential67 NGS PanelNGS (DNA) expanded panel targeting 67 clinically relevant and actionable genes (including mutations of the RAS/ RAF/MEK/MAP kinase signaling pathway)1) FFPE Block OR 10 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0011
BRCA1/2 Germline NGS & MLPA Panel NGS (DNA) panel targeting inherited BRCA 1 & 2 mutations with 100% coverage for all exons and exon/intron junctions through CNV analysis and MLPA technique to detect regulatory region & deep intronic mutations, large deletions/ duplications & large genomic rearrangement (LGR)1) 3ml Blood in EDTA tube(s)12-15 Working DaysS0034
BRCA1/2 Germline NGS PanelNGS (DNA) panel targeting inherited BRCA 1 & 2 mutations with 100% coverage for all exons and exon/intron junctions through CNV analysis1) 3ml Blood in EDTA tube(s)12-15 Working DaysS0013
BRAF PCR Panel PCR method to detect BRAF mutation at V600E hotspot in all solid tumours1) FFPE Block OR 5 Unstained Slides
2) 1 H&E Stained Slide
3) HPE report
10 Working DaysS0010
MSI PCR Panel PCR & Fragment Analysis based assays detecting microsatellite instability status for treatment options in all solid tumours1) FFPE Block OR 5 Unstained Slides
2) 3ml Blood in EDTA tube(s)
3) 1 H&E Stained Slide
4) HPE report
10 Working DaysS0012

Cancer TypeProduct NameGene Covered (Kindly refer to test form)Sample RequirementTAT on ReceiptCat. No.
MPN Fusion
(RNA)

ONCODEduce MPN BCR-ABL1 Qualitative Major & Minor PCR Panel
BCR-ABL1 fusion, e13/b2a2, e14/b3a2, e1a2 transcripts only
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
7 Working Days
B0001
MPN Fusion
(RNA)
ONCODEduce MPN BCR-ABLI Qualitative Atypical PCR Panel
All possible BCR-ABL1 fusions
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
10 Working Days
B0002
MPN Fusion
(RNA)
ONCODEduce CML ABL1 Kinase Domain Mutation NGS Panel Mutations in ABL1 kinase domain (amino acid positions 244-396)
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B0003
MPN Fusion
(RNA)
ONCODEduce Eosinophilia NGS Panel NGS panel to detect all fusions in PDGFRA (including FIP1L1-PDGFRA), PDGFRB, FGFR1, BCR, ABL1, FLT3 and JAK2 (including PCM1-JAK2)
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B0004
MPN Fusion
(RNA)
ONCODEduce MPN Fusion 87-gene NGS Panel 87 fusion genes including BCR-ABL1, PCM1-JAK2, PDGFRA, PDGFRB, FGFR1 rearrangements
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B0005
MPN Mutation
ONCODEduce MPN PCR Single Gene
1) JAK2 V617F & exon 12
OR
2) CALR
OR
3) MPL W515K/L/A & S505N
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B0006

B0007

B0008
MPN Mutation
ONCODEduce MPN PCR
Duo Genes
1) JAK2 V617F & exon 12 and CALR
OR
2) JAK2 V617F & exon 12 and MPL W515K/L/A & S505N
OR
3) CALR and MPL W515K/L/A & S505N
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B001P

B002P

B003P
MPN Mutation
ONCODEduce MPN PCR Panel (JAK2, CALR, MPL) JAK2 V617F & exon 12, CALR, MPL W515K/L/A, S505N
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B004P
MPN Mutation
ONCODEduce MPN Mutation 37-gene NGS Panel 37 genes mutation panel
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B0009
AML Fusion (RNA)
ONCODEduce PML-RARA Qualitative PCR Assay
All 3 transcript types PML-RARA
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
7 Working Days
B0010
AML Fusion (RNA)ONCODEduce RUNX1-RUNX1T1 + CBFB-MYH11 Qualitative PCR Panel
RUNX1-RUNX1T1 and
CBFB-MYH11
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
7 Working Days
B0011
AML Fusion (RNA)ONCODEduce AML BCR-ABL1 Qualitative Major & Minor PCR Panel
BCR-ABL1 fusion, e13/b2a2, e14/b3a2, e1a2 transcripts only
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
7 Working Days
B0012
AML Fusion (RNA) ONCODEduce AML ABL1 Kinase Domain Mutation NGS Pane Mutations in ABL1 kinase domain (amino acid positions 244-396)
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B0013
AML Fusion (RNA)ONCODEduce AML Fusion 11-gene NGS Panel
11 fusion genes including RUNX1, CBFB, RARA, BCR, ABL1, MLL/KMT2A
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
10 Working Days
B0014
AML Fusion (RNA) ONCODEduce AML Fusion 87-gene NGS Panel 87-gene fusions panel
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working Days
B0015
AML Package Mutation & Fusion (DNA + RNA) ONCODEduce AML Combo (Mutation & Fusion) NGS panel Mutation: 11 genes including FLT3-ITD & TKD, NPM1, CEBPA, IDH1/2, KIT, RUNX1, TP53

Fusion: 11 genes including RUNX1, CBFB, RARA, BCR, ABL1, MLL/KMT2A
Blood 6ml EDTA
OR
Marrow Aspirate 5ml EDTA
OR
Aspirate 4 smears with adequate cellularity (only for NGS panel)
10 Working
Days
B005P
AML/MDS Mutation
ONCODEduce AML FLT3 (ITD & TKD) + NPM1 Qualitative PCR Panel
FLT3-ITD & FLT3-TKD D835/I836, NPM1
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
10 Working
Days
B0016
AML/MDS Mutation
ONCODEduce AML Core Mutation 11-gene NGS Panel 11 genes including FLT3-ITD & TKD, NPM1, CEBPA, IDH1/2, KIT, RUNX1, TP53
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
10 Working
Days
B0017
AML/MDS Mutation
ONCODEduce AML/MDS Mutation 37-gene NGS Panel 37 genes mutation panelBlood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working
Days
B0018
ALL Fusion
(RNA)

ONCODEduce ALL BCR-ABL1 Qualitative Major & Minor PCR Panel
BCR-ABL1 fusion, e13/b2a2, e14/b3a2, e1a2 transcripts only
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
7 Working
Days
B0019
ALL Fusion
(RNA)
ONCODEduce ALL ABL1 Kinase Domain Mutation NGS Panel Mutations in ABL1 kinase domain (amino acid positions 244-396)
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working
Days
B0020
ALL Fusion
(RNA)
ONCODEduce B-ALL Fusion 87-gene NGS Panel 87-gene fusions panel (includes
BCR-ABL1, Ph-like BCR-ABL1 negative B-ALL)
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working
Days
B0021
ALL Fusion
(RNA)
ONCODEduce T-ALL Fusion 87-gene NGS Panel 87-gene fusions panel (includes fusions implicated in T-ALL)
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
Aspirate 2 smears with adequate cellularity (only for NGS panel)
15 Working
Days
B0022
NHL
ONCODEduce BRAF V600E Qualitative PCR Panel
BRAF V600E
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
FFPE Block (minimal surface area: 5mm2) OR 10 unstained Slides (10μm thickness, >5mm2 sections), with at least 30% tumour cellularity & 1 H&E slide with HPE report
15 Working
Days
B0023
NHL
ONCODEduce MYD88 L265P Qualitative PCR Panel
MYD88 L265P
Blood 3ml EDTA
OR
Marrow Aspirate 1-2.5ml EDTA
OR
FFPE Block (minimal surface area: 5mm2) OR 10 unstained Slides (10μm thickness, >5mm2 sections), with at least 30% tumour cellularity & 1 H&E slide with HPE report
15 Working
Days

COVID-19 RT-PCR SAMPLE REPORT

Scroll to Top

ONCODEcipher Microsatellite Instability (MSI) PCR Panel

Product Description:

PCR and fragment analysis-based assay targeting MSI to detect the increase in length of the microsatellite segment by comparing microsatellite allele size variations between normal and tumour samples in five mononucleotide repeat markers for the discovery of treatment options such as immunotherapy.

Target Markers -- NR-21, NR-24, BAT-26, BAT-25, & MONO-27

Technique:

Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher BRAF PCR Panel

Product Description:

PCR method to detect BRAF mutation at V600E hotspot in all solid tumours especially in melanoma to provide treatment options.

Gene Covered -- BRAF V600E

Technique:

Polymerase Chain Reaction (PCR)

Test Methodology:

DNA extracted from FFPE tissue is subjected to PCR with primers targeting the hotspot region & amplicons are separated and identified by agarose gel electrophoresis.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher BRCA1/2 Germline NGS & MLPA Panel

Product Description:

NGS and MLPA panel targeting germline BRCA 1 & 2 mutations with 100% coverage including SNV, small InDels, large deletions & duplications, and large genomic rearrangement (LGR) to identify the risk of hereditary breast, ovarian, prostate, pancreatic cancers; and to seek for treatment options.

Genes Covered -- 100% coverage of BRCA 1 & 2 germline mutations

Technique:

Next Generation Sequencing (NGS) & Multiplex Ligation-Dependent Probe Amplification (MLPA)

Test Methodology:

NGS: DNA extracted from blood is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using proprietary bioinformatics pipelines.

MLPA: DNA extracted from blood is subjected to Multiplex Ligation-Dependent Probe Amplification. Fluorescent labelled amplicons are separated and quantified by capillary electrophoresis.

Specimen Requirements:

3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

12-15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Liquid28 NGS Panel

Product Description:

Non-invasive cell free circulating tumour DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the 28 genes which are known to play a role in of solid tumours using only the blood of the patients.

Highlighted Genes -- EGFR, BRAF, KRAS, ESR1, FGFR, PIK3CA, TP53, ALK resistance etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

15ml Blood in cfDNA tubes

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Microsatellite Instability (MSI) PCR Panel

Product Description:

PCR and fragment analysis-based assay targeting MSI to detect the increase in length of the microsatellite segment by comparing microsatellite allele size variations between normal and tumour samples in five mononucleotide repeat markers for the discovery of treatment options such as immunotherapy.

Target Markers -- NR-21, NR-24, BAT-26, BAT-25, & MONO-27

Technique:

Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Microsatellite Instability (MSI) PCR Panel

Product Description:

PCR and fragment analysis-based assay targeting MSI to detect the increase in length of the microsatellite segment by comparing microsatellite allele size variations between normal and tumour samples in five mononucleotide repeat markers for the discovery of treatment options such as immunotherapy.

Target Markers -- NR-21, NR-24, BAT-26, BAT-25, & MONO-27

Technique:

Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher BRCA1/2 Germline NGS & MLPA Panel

Product Description:

NGS and MLPA panel targeting germline BRCA 1 & 2 mutations with 100% coverage including SNV, small InDels, large deletions & duplications, and large genomic rearrangement (LGR) to identify the risk of hereditary breast, ovarian, prostate, pancreatic cancers; and to seek for treatment options.

Genes Covered -- 100% coverage of BRCA 1 & 2 germline mutations

Technique:

Next Generation Sequencing (NGS) & Multiplex Ligation-Dependent Probe Amplification (MLPA)

Test Methodology:

NGS: DNA extracted from blood is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using proprietary bioinformatics pipelines.

MLPA: DNA extracted from blood is subjected to Multiplex Ligation-Dependent Probe Amplification. Fluorescent labelled amplicons are separated and quantified by capillary electrophoresis.

Specimen Requirements:

3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

12-15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Liquid28 NGS Panel

Product Description:

Non-invasive cell free circulating tumour DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the 28 genes which are known to play a role in of solid tumours using only the blood of the patients.

Highlighted Genes -- EGFR, BRAF, KRAS, ESR1, FGFR, PIK3CA, TP53, ALK resistance etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

15ml Blood in cfDNA tubes

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Microsatellite Instability (MSI) PCR Panel

Product Description:

PCR and fragment analysis-based assay targeting MSI to detect the increase in length of the microsatellite segment by comparing microsatellite allele size variations between normal and tumour samples in five mononucleotide repeat markers for the discovery of treatment options such as immunotherapy.

Target Markers -- NR-21, NR-24, BAT-26, BAT-25, & MONO-27

Technique:

Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher BRAF PCR Panel

Product Description:

PCR method to detect BRAF mutation at V600E hotspot in all solid tumours especially in melanoma to provide treatment options.

Gene Covered -- BRAF V600E

Technique:

Polymerase Chain Reaction (PCR)

Test Methodology:

DNA extracted from FFPE tissue is subjected to PCR with primers targeting the hotspot region & amplicons are separated and identified by agarose gel electrophoresis.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher BRCA1/2 Germline NGS & MLPA Panel

Product Description:

NGS and MLPA panel targeting germline BRCA 1 & 2 mutations with 100% coverage including SNV, small InDels, large deletions & duplications, and large genomic rearrangement (LGR) to identify the risk of hereditary breast, ovarian, prostate, pancreatic cancers; and to seek for treatment options.

Genes Covered -- 100% coverage of BRCA 1 & 2 germline mutations

Technique:

Next Generation Sequencing (NGS) & Multiplex Ligation-Dependent Probe Amplification (MLPA)

Test Methodology:

NGS: DNA extracted from blood is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using proprietary bioinformatics pipelines.

MLPA: DNA extracted from blood is subjected to Multiplex Ligation-Dependent Probe Amplification. Fluorescent labelled amplicons are separated and quantified by capillary electrophoresis.

Specimen Requirements:

3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

12-15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Microsatellite Instability (MSI) PCR Panel

Product Description:

PCR and fragment analysis-based assay targeting MSI to detect the increase in length of the microsatellite segment by comparing microsatellite allele size variations between normal and tumour samples in five mononucleotide repeat markers for the discovery of treatment options such as immunotherapy.

Target Markers -- NR-21, NR-24, BAT-26, BAT-25, & MONO-27

Technique:

Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher BRCA1/2 Germline NGS & MLPA Panel

Product Description:

NGS and MLPA panel targeting germline BRCA 1 & 2 mutations with 100% coverage including SNV, small InDels, large deletions & duplications, and large genomic rearrangement (LGR) to identify the risk of hereditary breast, ovarian, prostate, pancreatic cancers; and to seek for treatment options.

Genes Covered -- 100% coverage of BRCA 1 & 2 germline mutations

Technique:

Next Generation Sequencing (NGS) & Multiplex Ligation-Dependent Probe Amplification (MLPA)

Test Methodology:

NGS: DNA extracted from blood is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using proprietary bioinformatics pipelines.

MLPA: DNA extracted from blood is subjected to Multiplex Ligation-Dependent Probe Amplification. Fluorescent labelled amplicons are separated and quantified by capillary electrophoresis.

Specimen Requirements:

3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

12-15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Breast & Ovarian Core28 NGS Panel

Product Description:

FFPE DNA panel targeting 28 clinically relevant and actionable genes commonly mutated in breast & ovarian cancer to provide treatment options & prognostic indications.

Highlighted Genes -- Somatic BRCA1 & BRCA2, ESR1, PIK3CA, TP53, etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

DNA extracted from FFPE tissue is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial clinical bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

FFPE tissue (FFPE block or 10 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Liquid28 NGS Panel

Product Description:

Non-invasive cell free circulating tumour DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the 28 genes which are known to play a role in of solid tumours using only the blood of the patients.

Highlighted Genes -- EGFR, BRAF, KRAS, ESR1, FGFR, PIK3CA, TP53, ALK resistance etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

15ml Blood in cfDNA tubes

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Microsatellite Instability (MSI) PCR Panel

Product Description:

PCR and fragment analysis-based assay targeting MSI to detect the increase in length of the microsatellite segment by comparing microsatellite allele size variations between normal and tumour samples in five mononucleotide repeat markers for the discovery of treatment options such as immunotherapy.

Target Markers -- NR-21, NR-24, BAT-26, BAT-25, & MONO-27

Technique:

Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher BRAF PCR Panel

Product Description:

PCR method to detect BRAF mutation at V600E hotspot in all solid tumours especially in melanoma to provide treatment options.

Gene Covered -- BRAF V600E

Technique:

Polymerase Chain Reaction (PCR)

Test Methodology:

DNA extracted from FFPE tissue is subjected to PCR with primers targeting the hotspot region & amplicons are separated and identified by agarose gel electrophoresis.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Liquid28 NGS Panel

Product Description:

Non-invasive cell free circulating tumour DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the 28 genes which are known to play a role in of solid tumours using only the blood of the patients.

Highlighted Genes -- EGFR, BRAF, KRAS, ESR1, FGFR, PIK3CA, TP53, ALK resistance etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

15ml Blood in cfDNA tubes

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Colon Essential67 + MSI Panel

Product Description:

FFPE DNA panel targeting 67 relevant genetic mutations in colon cancer AND microsatellite instability (MSI) status to provide treatment options & prognostic indications.

Highlighted Genes -- Mutations of RAS/ RAF/ MEK/ MAP kinase signalling pathway

Technique:

Next Generation Sequencing (NGS) AND
Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

Essential 67 NGS Panel
DNA extracted from FFPE tissue is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial clinical bioinformatics pipelines and annotation is done using proprietary and public databases.

MSI PCR & Fragment Analysis Panel
DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 10-15 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Lung Absolute 2.0 NGS Panel

Product Description:

FFPE TNA panel targeting both fusions and mutations in 15 genes commonly altered in lung cancer to provide treatment options & prognostic indications.

Highlighted Genes -- Fusion: ALK, ROS1, MET, NTRK, etc.; Mutation: EGFR, ERBB2, BRAF, KRAS, etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Total Nucleic Acid extracted from FFPE tissue is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial clinical bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

FFPE tissue (FFPE block or 10 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Liquid28 NGS Panel

Product Description:

Non-invasive cell free circulating tumour DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the 28 genes which are known to play a role in of solid tumours using only the blood of the patients.

Highlighted Genes -- EGFR, BRAF, KRAS, ESR1, FGFR, PIK3CA, TP53, ALK resistance etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

15ml Blood in cfDNA tubes

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce B-ALL Fusion 87 gene NGS Panel

Product Description:

NGS Panel detecting 87 gene fusions implicated in B-ALL including fusions identifying Ph-like BCR-ABL1 negative B-ALL.

Highlighted Genes -- ABL1, ABL2, CRLF2, CSF1R, EPOR, ETV6, JAK2, KMT2A, P2RY8, PAX5, PDGFRA, PDGFRB, PTK2B, TCF3, TYK2

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce B-ALL Fusion 87 gene NGS Panel

Product Description:

NGS Panel detecting 87 gene fusions implicated in B-ALL including fusions identifying Ph-like BCR-ABL1 negative B-ALL.

Highlighted Genes -- ABL1, ABL2, CRLF2, CSF1R, EPOR, ETV6, JAK2, KMT2A, P2RY8, PAX5, PDGFRA, PDGFRB, PTK2B, TCF3, TYK2

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce ABL1 Kinase Domain Mutation NGS Panel

Product Description:

NGS Panel to detect Tyrosine Kinase Inhibitors (TKIs) resistance mutations in ABL1 kinase domain and BCR-ABL1 fusions.

Gene Covered -- BCR-ABL1 fusion and mutation in ABL1 kinase domain (amino acid positions 244-396)

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce MDS Mutation 37-gene NGS Panel

Product Description:

NGS Panel targeting 37 gene mutations that allows a broader exploration of the gene frequently implicated in the diagnosis, treatment and prognostication of MDS.

Highlighted Genes -- ASXL1, DNMT3A, EZH2, KRAS, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, ZRSR2 etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

DNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce AML Core NGS Panel

Product Description:

NGS Panel targeting 13 gene mutations commonly altered in AML for the diagnosis, prognostic, and therapy selection.

Highlighted Genes -- FLT3-ITD & TKD, NPM1, CEBPA, IDH1/2, KIT, RUNX1, TP53, etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

DNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases. .

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce AML Combo (Mutation & Fusion) NGS Panel

Product Description:

Comprehensive package for AML for the diagnosis, prognostic, and therapy selection targeting genes mutations (DNA mutation) in hotspot regions/selected exons of 13 genes commonly mutated in AML, and the commonest rearrangements (RNA fusions) in 11 genes implicated in AML.

Highlighted Genes -- Mutation: FLT3-ITD & TKD, NPM1, CEBPA, IDH1/2, KIT, RUNX1, TP53, etc.; Fusion: RUNX1, CBFB, RARA, BCR, ABL1, MLL/KMT2A, etc.;

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

DNA and RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

6ml of Blood or Marrow Aspirate in EDTA tube or
4 aspirate smears with adequate cellularity

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce B-ALL Fusion 87 gene NGS Panel

Product Description:

NGS Panel detecting 87 gene fusions implicated in B-ALL including fusions identifying Ph-like BCR-ABL1 negative B-ALL.

Highlighted Genes -- ABL1, ABL2, CRLF2, CSF1R, EPOR, ETV6, JAK2, KMT2A, P2RY8, PAX5, PDGFRA, PDGFRB, PTK2B, TCF3, TYK2

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce ABL1 Kinase Domain Mutation NGS Panel

Product Description:

NGS Panel to detect Tyrosine Kinase Inhibitors (TKIs) resistance mutations in ABL1 kinase domain and BCR-ABL1 fusions.

Gene Covered -- BCR-ABL1 fusion and mutation in ABL1 kinase domain (amino acid positions 244-396)

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce MDS Mutation 37-gene NGS Panel

Product Description:

NGS Panel targeting 37 gene mutations that allows a broader exploration of the gene frequently implicated in the diagnosis, treatment and prognostication of MDS.

Highlighted Genes -- ASXL1, DNMT3A, EZH2, KRAS, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, ZRSR2 etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

DNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce MPN PCR Panel

Product Description:

Qualitative PCR based panel to detect the presence of JAK2 V617F, JAK2 exon 12, Calreticulin and MPL W515K/L/A & S505N mutations which is useful in the assessment of Myeloproliferative conditions.

Genes Covered-- JAK2 V617F & exon 12, CALR, MPL W515K/L/A & S505N mutations

Technique:

Polymerase Chain Reaction (PCR)

Test Methodology:

DNA extracted from blood/ marrow is subjected to PCR with primers targeting these hotspot regions and/or variants. JAK2 exon 12 & CALR amplicons are separated by capillary electrophoresis and identified by label and size, while JAK2 V617F & MPL amplicons are separated by agarose gel electrophoresis and identified by size.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce B-ALL Fusion 87 gene NGS Panel

Product Description:

NGS Panel detecting 87 gene fusions implicated in B-ALL including fusions identifying Ph-like BCR-ABL1 negative B-ALL.

Highlighted Genes -- ABL1, ABL2, CRLF2, CSF1R, EPOR, ETV6, JAK2, KMT2A, P2RY8, PAX5, PDGFRA, PDGFRB, PTK2B, TCF3, TYK2

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce Eosinophilia NGS Panel

Product Description:

NGS Panel to detect all fusions involving 8 genes: PDGFRA (including FIP1L1-PDGFRA), PDGFRB, FGFR1, BCR, ABL1, FLT3, ETV6 & JAK2 (including PCM1-JAK2) & mutation in KIT.

Genes Covered-- PDGFRA, PDGFRB, ABL1, BCR, ETV6, FGFR1, FLT3, JAK2 & KIT

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEduce ABL1 Kinase Domain Mutation NGS Panel

Product Description:

NGS Panel to detect Tyrosine Kinase Inhibitors (TKIs) resistance mutations in ABL1 kinase domain and BCR-ABL1 fusions.

Gene Covered -- BCR-ABL1 fusion and mutation in ABL1 kinase domain (amino acid positions 244-396)

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.